Pharma BD Deal Intelligence

GlaxoSmithKline plc / Vir Biotechnology Inc.

2020 · Co-Development · $595M · Complete

Announcement Sentiment

Strongly positive

Outcome Score

Mixed — partial payoff, real shortfalls.

GSK and Vir Biotechnology partnered to co-develop monoclonal antibodies for coronaviruses, leading to sotrovimab for COVID-19 and later expanding to influenza therapeutics.

Key facts

Announced Apr 06, 2020
Deal value $595M
Deal type Co-Development
Therapeutic area Infectious Disease
Indications COVID-19, Influenza
Key assets sotrovimab (VIR-7831), VIR-7832
Mechanism Anti-SARS-CoV-2 monoclonal antibody

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals